NCT03425331View on ClinicalTrials.gov

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

May 18, 2020

Study Completion Date

November 28, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Ipilimumab

Ipilimumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells

DRUG

Nivolumab

Nivolumab is a type of immunotherapy. Immunotherapy works by stimulating the body's own immune system to attack cancer cells

Trial Locations (3)

02214

Massachusetts General Hospital, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER